Brought to you by

Pfizer gets rights to Hydra Biosciences' TRPV3 antagonists
27 Aug 2007
Executive Summary
Hydra Biosciences (therapeutics that target ion channels) and Pfizer have teamed up to develop TRPV3 antagonists for pain.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement